+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Mellitus Treatment Market by Drug Class, Route Of Administration, Distribution Channel, Pricing Tier, End User, Line Of Therapy, Patient Age Group - Global Forecast to 2030- Product Image
Type 2 Diabetes Mellitus Treatment Market by Drug Class, Route Of Administration, Distribution Channel, Pricing Tier, End User, Line Of Therapy, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Type 2 Diabetes Mellitus Treatment Market by Drug Class, Route Of Administration, Distribution Channel, Pricing Tier, End User, Line Of Therapy, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079010
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Type 2 Diabetes Mellitus presents a complex, evolving challenge for the healthcare and pharmaceutical ecosystem. Senior decision-makers require an actionable, strategic view of this market to capitalize on emerging therapies, navigate regulatory shifts, and address changing patient needs efficiently.

Market Snapshot: Type 2 Diabetes Market

The global market for Type 2 Diabetes treatment is characterized by sustained growth as patient populations expand and therapeutic approaches diversify. Robust innovation is leading to new product approvals across injectable and oral modalities. Advanced digital health tools are gaining traction, supplementing traditional care methods. Regional disparities persist in therapy access, technology adoption, and reimbursement models, demanding careful strategy from industry leaders.

Scope & Segmentation

This comprehensive research offers clarity across the full Type 2 Diabetes care value chain, with granular segmentation and trend analysis. Segments covered include:

  • Drug Classes: Biguanides (metformin), DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin), GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide), insulin (intermediate, long-acting, premixed, rapid-acting), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), sulfonylureas (glimepiride, glipizide, glyburide), and thiazolidinediones (pioglitazone, rosiglitazone).
  • Routes of Administration: Injectable delivery (auto-injectors, pre-filled pens, pumps, vials and syringes) and oral formulations (combination therapy, monotherapy).
  • Distribution Channels: Hospital pharmacies (inpatient, outpatient), online pharmacy platforms (e-commerce, telepharmacy), and retail pharmacies (chain, independent).
  • Pricing Tiers: Branded products and generics (injectable and oral generics).
  • End Users: Clinics, homecare, hospitals, and research institutes.
  • Lines of Therapy: Ranging from first through fourth line regimens.
  • Patient Age Groups: Adult, elderly, and pediatric populations.
  • Regional Focus: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East, and Africa (including UK, Germany, France, Russia, UAE, South Africa, and others), and Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Company Analysis: Detailed review of leaders including Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Merck & Co., Inc., Boehringer Ingelheim, Johnson & Johnson, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Key Takeaways: Executive Insights for Senior Decision-Makers

  • Therapy management is transitioning from monotherapy to advanced combination and dual agonist approaches, driven by peptide engineering as well as digital monitoring technologies.
  • Digital health solutions — such as remote monitoring, mobile apps, and telemedicine — are enabling personalized care, increasing adherence, and allowing for timely dosing adjustments based on real-world data.
  • Industry consolidation is influencing competitive dynamics, as key players form strategic acquisitions and collaborations to accelerate development and strengthen supply chains.
  • Regional disparities impact access, with North America excelling in high-value therapy adoption and emerging markets focusing on affordable generics and basic access infrastructure.
  • Distribution and channel strategy is shifting, with hospital, online, and retail settings each playing distinct roles in access, patient engagement, and cost-management.
  • Patient segmentation—by age, therapy line, and access pathway—is shaping device design, adherence programs, and pricing decisions at both global and local levels.

Tariff Impact: Preparing for US Market Changes (2025)

New United States tariffs on imported pharmaceutical ingredients and finished diabetes therapies in 2025 will challenge supply chains and increase production costs for manufacturers. Health systems are already reevaluating sourcing and formulary strategies, with some stakeholders expanding domestic manufacturing to maintain price stability and continuity of care. Strategic supplier partnerships and diversified sourcing play a critical role in mitigating these disruptions.

Methodology & Data Sources

This report integrates primary research—over 50 interviews with senior industry stakeholders, clinicians, payers, and supply chain experts—with exhaustive secondary data from company filings, clinical trial registries, regulatory sources, and trade journals. Rigorous data triangulation and cross-verification with proprietary databases ensure segmentation accuracy and nuanced insights.

Why This Report Matters

  • Gain actionable intelligence to anticipate disruptions, optimize resource allocation, and shape future portfolios with confidence.
  • Leverage trend analysis to refine engagement, pricing, and market access strategies tailored to diverse regional, demographic, and technological contexts.
  • Empower leadership teams with evidence-based insights for risk management, investment prioritization, and innovation.

Conclusion

This Type 2 Diabetes market research report provides senior executives with the clarity and strategic direction needed in an evolving therapeutic landscape. By leveraging these insights, organizations can position themselves to meet future challenges and capture emerging opportunities effectively.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 2 Diabetes Mellitus Treatment Market, by Drug Class
8.1. Introduction
8.2. Biguanides
8.2.1. Metformin
8.3. Dpp-4 Inhibitors
8.3.1. Alogliptin
8.3.2. Linagliptin
8.3.3. Saxagliptin
8.3.4. Sitagliptin
8.4. Glp-1 Receptor Agonists
8.4.1. Dulaglutide
8.4.2. Exenatide
8.4.3. Liraglutide
8.4.4. Semaglutide
8.5. Insulin
8.5.1. Intermediate
8.5.2. Long Acting
8.5.3. Premixed
8.5.4. Rapid Acting
8.6. Sglt2 Inhibitors
8.6.1. Canagliflozin
8.6.2. Dapagliflozin
8.6.3. Empagliflozin
8.6.4. Ertugliflozin
8.7. Sulfonylureas
8.7.1. Glimepiride
8.7.2. Glipizide
8.7.3. Glyburide
8.8. Thiazolidinediones
8.8.1. Pioglitazone
8.8.2. Rosiglitazone
9. Type 2 Diabetes Mellitus Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Auto Injectors
9.2.2. Pre Filled Pens
9.2.3. Pumps
9.2.4. Vials And Syringes
9.3. Oral
9.3.1. Combination Therapy
9.3.2. Monotherapy
10. Type 2 Diabetes Mellitus Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Online Pharmacies
10.3.1. E Commerce Platforms
10.3.2. Telepharmacy
10.4. Retail Pharmacies
10.4.1. Chain
10.4.2. Independent
11. Type 2 Diabetes Mellitus Treatment Market, by Pricing Tier
11.1. Introduction
11.2. Branded
11.3. Generic
11.3.1. Injectable Generics
11.3.2. Oral Generics
12. Type 2 Diabetes Mellitus Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
12.5. Research Institutes
13. Type 2 Diabetes Mellitus Treatment Market, by Line Of Therapy
13.1. Introduction
13.2. First Line
13.3. Fourth Line
13.4. Second Line
13.5. Third Line
14. Type 2 Diabetes Mellitus Treatment Market, by Patient Age Group
14.1. Introduction
14.2. Adults
14.3. Elderly
14.4. Pediatric
15. Americas Type 2 Diabetes Mellitus Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Type 2 Diabetes Mellitus Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Type 2 Diabetes Mellitus Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novo Nordisk A/S
18.3.2. Eli Lilly and Company
18.3.3. Sanofi S.A.
18.3.4. AstraZeneca PLC
18.3.5. Merck & Co., Inc.
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Johnson & Johnson
18.3.8. Novartis AG
18.3.9. Pfizer Inc.
18.3.10. Takeda Pharmaceutical Company Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TYPE 2 DIABETES MELLITUS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. TYPE 2 DIABETES MELLITUS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. TYPE 2 DIABETES MELLITUS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TYPE 2 DIABETES MELLITUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TYPE 2 DIABETES MELLITUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYPE 2 DIABETES MELLITUS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INTERMEDIATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PREMIXED, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY AUTO INJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRE FILLED PENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TELEPHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY FOURTH LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 129. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 131. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 133. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 134. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 136. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 137. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 139. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 140. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 144. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 145. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 146. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 148. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 154. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 157. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 159. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 160. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 162. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 164. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 165. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 166. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 168. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 250. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 252. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 254. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 255. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 257. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 258. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 260. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 261. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 266. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 267. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, 2018-2030 (USD MILLION)
TABLE 272. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 273. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2030 (USD MILLION)
TABLE 274. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 275. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, 2018-2030 (USD MILLION)
TABLE 277. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2030 (USD MILLION)
TABLE 278. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 280. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 281. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 283. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 284. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 285. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRICING TIER, 2018-2030 (USD MILLION)
TABLE 286. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 287. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 289. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. RUSSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Type 2 Diabetes Mellitus Treatment market report include:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Type 2 Diabetes Mellitus Treatment - Global Strategic Business Report - Product Image

Type 2 Diabetes Mellitus Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034 - Product Image

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034

  • Report
  • 300 Pages
  • Global
From
Liraglutide and Semaglutide - Global Strategic Business Report - Product Image

Liraglutide and Semaglutide - Global Strategic Business Report

  • Report
  • 451 Pages
  • Global
From
Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.